See more : Cover Technologies Inc. (COVE.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JonDeTech Sensors AB (publ) (JDT.ST) Income Statement Analysis – Financial Results
- Melhus Sparebank (MELG.OL) Income Statement Analysis – Financial Results
- BAIC Motor Corporation Limited (2B5.VI) Income Statement Analysis – Financial Results
- Electra Battery Materials Corporation (ELBM) Income Statement Analysis – Financial Results
- Sollensys Corp. (SOLS) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Momentum trading is one of my favorite strategies. Legendary trader Mark Minervini, who won the U.S. investing championship in 1997 and 2021, used momentum trading strategies to win.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , May 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2024, the Human Capital Management Committee of...
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial...
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to...
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ trial in 2H24 Presented positive long-term del-desiran data from...
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of...
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by...
Source: https://incomestatements.info
Category: Stock Reports